Trial Profile
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC 681239, NSC 724772) for Patients With High Allelic Ratio FLT3/ITD
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexrazoxane (Primary) ; Sorafenib (Primary) ; Asparaginase; Cytarabine; Cytarabine; Daunorubicin; Etoposide; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms AAML1031
- 12 Dec 2023 Results deriving samples from this study, assessing the utility of the PGx-based ACS10 score, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 20 Feb 2023 Results (n=80) assessing cytokine levels in diagnostic peripheral blood plasma of pediatric AML patients and determined correlation with outcome by deriving peripheral blood plasma of pediatric AML patients , published in the Pediatric Hematology and Oncology
- 13 Dec 2022 Results assessing the retrospective impact of an updated risk classification on treatment allocation for de novo AML, by deriving samples from NCT01407757 and NCT01371981 , presented at the 64th American Society of Hematology Annual Meeting and Exposition